Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evivo + medium-chain triglyceride oil
- Development stage
- Unknown
- Lead developer
- Evolve BioSystems
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Evivo with medium-chain triglyceride (MCT) oil is a live biotherapeutic product developed by Evolve BioSystems, Inc. It consists of activated *Bifidobacterium infantis* EVC001 (ActiBif) formulated in MCT oil as a delivery vehicle. Designed for use in hospital settings, particularly Neonatal Intensive Care Units (NICUs), the product aims to restore the infant gut microbiome to its natural state. When administered alongside breast milk, *B. infantis* EVC001 utilizes human milk oligosaccharides (HMOs) to dominate the gut environment, thereby reducing the prevalence of potentially pathogenic bacteria such as *Escherichia coli*, *Clostridia*, *Staphylococcus*, and *Streptococcus*. This intervention is primarily indicated for the treatment and prevention of infant gut dysbiosis.
- Other names
- Bifidobacterium infantis EVC001 + medium-chain triglyceride oilactivated Bifidobacterium infantis EVC001 with MCT oil
Beyond the preview
Go deeper on Evivo + medium-chain triglyceride oil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Evivo + medium-chain triglyceride oil.